ArticlePharmacoEconomics2019

Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.

Holly Guy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.